Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:off-label_drug_use
|
| gptkbp:legalStatus |
varies by country
|
| gptkbp:mechanismOfAction |
gptkb:NMDA_receptor_antagonist
glutamatergic modulation |
| gptkbp:monitors |
yes
|
| gptkbp:notFDAApprovedFor |
gptkb:depression
pain PTSD |
| gptkbp:prescribes |
psychiatrists
pain specialists |
| gptkbp:refersTo |
gptkb:Ketamine
|
| gptkbp:relatedTo |
gptkb:esketamine
|
| gptkbp:riskFactor |
potential for abuse
dependence |
| gptkbp:routeOfAdministration |
oral
intravenous intranasal sublingual |
| gptkbp:sideEffect |
nausea
dissociation hallucinations elevated blood pressure urinary tract symptoms |
| gptkbp:usedFor |
gptkb:obsessive-compulsive_disorder
gptkb:post-traumatic_stress_disorder treatment-resistant depression chronic pain suicidal ideation anxiety disorders bipolar depression |
| gptkbp:bfsParent |
gptkb:Antidepressants
|
| gptkbp:bfsLayer |
6
|
| https://www.w3.org/2000/01/rdf-schema#label |
Ketamine (off-label)
|